Idiopathic Pulmonary Fibrosis. Idiopathic pulmonary fibrosis
Conditions
Interventions
Intervention 1: Intervention group: In addition to pirfenidone tablets, each subject in the intervention group will take an oral deep lung support capsule three times a day with water. The way to take
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: Forced vital capacity (FVC) greater than 40% and less than or equal to 90% Diffusing capacity of the lungs for carbon monoxide (DLCO) greater than or equal to 40% and less than or equal to 90%
Exclusion criteria
Exclusion criteria: Having an FEV1/FVC ratio of less than 0.8 (after bronchodilator administration) at screening Suffering from other interstitial lung diseases, history of asthma or chronic lung disease, active infection, being treated with other IPF treatment methods such as immunosuppressives and cytokine regulating agents. History of unstable or worsening heart or lung disease (except IPF) in the past six months Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical symptoms (cough and shortness of breath). Timepoint: Once before starting treatment and once 3 months after that. Method of measurement: "Rate of perceived exertion" and "cough symptom score" scales.;Pulmonary function tests. Timepoint: Once before starting treatment and once 3 months after that. Method of measurement: by spirometry.;TGF-ß serum level. Timepoint: Once before starting treatment and once 3 months after that. Method of measurement: by blood sample testing. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSasan Tavana
Shahid Beheshti University of Medical Sciences
Outcome results
None listed